BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

...Regeneron’s osteoarthritis mAb meets in two pivotal trials Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said osteoarthritis therapy fasinumab...
...Staff Viaskin Peanut (DBV-712) PNT2002 KarXT, LY246708 plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV...
BioCentury | Jun 20, 2020
Product Development

Regeneron’s commercial future

...NYSE:TEVA; Tel Aviv:TEVA) and Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) have ex-U.S. rights to anti-NGF mAb fasinumab...
BioCentury | Apr 19, 2019
Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

...Aviv:TEVA) are also developing a mAb against NGF. The partners reported in August that their fasinumab...
BioCentury | Oct 26, 2018
Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

...Tel Aviv:TEVA) are also developing a mAb against NGF. The partners reported in August that fasinumab...
...of OA; safety Status: Additional Phase III data Milestone: Submit NDA (2H19) Jennie Walters fasinumab (MT-5547, REGN475, SAR164877) tanezumab...
BioCentury | Oct 24, 2018
Clinical News

Detailed data for Pfizer, Lilly anti-NGF mAb highlighted at ACR/ARHP

...Tel Aviv:TEVA) are also developing a mAb against NGF. The partners reported in August that fasinumab...
...Anti-NGF mAb Meets 16-Week Endpoints in Phase III for OA Pain" ). Jennie Walters fasinumab (MT-5547, REGN475, SAR164877) tanezumab...
BioCentury | Aug 17, 2018
Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

...Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the...
...on a risk-benefit analysis (see “Regeneron Halting Higher Doses in Fasinumab Trials” ). Teva shares fasinumab’s...
...subscale score Status: Phase III data Milestone: Additional Phase III data (2021) Chris Lieu fasinumab (MT-5547, REGN475, SAR164877) Mitsubishi...
BioCentury | Aug 16, 2018
Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

...Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the...
...on a risk-benefit analysis (see “Regeneron Halting Higher Doses in Fasinumab Trials” ). Teva shares fasinumab’s...
...York on Thursday and was up NIS3.64 to NIS84.30 in Tel Aviv. Chris Lieu fasinumab (MT-5547, REGN475, SAR164877) Mitsubishi...
BioCentury | Jul 20, 2018
Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

...is also developing a mAb against NGF that had been on clinical hold. The company's fasinumab...
BioCentury | Jul 18, 2018
Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

...is also developing a mAb against NGF that had been on clinical hold. The company's fasinumab...
BioCentury | May 4, 2018
Clinical News

Regeneron halting higher doses in fasinumab trials

...said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab...
...but declined to disclose details about the higher doses or whether the analysis was planned. Fasinumab...
...NA Endpoint: NA Status: Phase III amended Milestone: Phase III data (2018) Jennie Walters fasinumab (MT-5547, REGN475, SAR164877) Mitsubishi...
Items per page:
1 - 10 of 45